Cell and Gene Therapy Catapult
@cgtcatapult.bsky.social
We create powerful collaborations which overcome challenges to the advancement of the ATMP sector, supporting advanced therapy development to ensure patients benefit from their immense potential.
A new study published by the CGT Catapult & the Office of Health Economics presents a new method of quantifying the economic impact of cell & gene therapies.
The research indicates that wider adoption of advanced therapies could unlock billions for the UK economy.
Read the study: lnkd.in/eGDdTXwN
The research indicates that wider adoption of advanced therapies could unlock billions for the UK economy.
Read the study: lnkd.in/eGDdTXwN
October 21, 2025 at 9:05 AM
A new study published by the CGT Catapult & the Office of Health Economics presents a new method of quantifying the economic impact of cell & gene therapies.
The research indicates that wider adoption of advanced therapies could unlock billions for the UK economy.
Read the study: lnkd.in/eGDdTXwN
The research indicates that wider adoption of advanced therapies could unlock billions for the UK economy.
Read the study: lnkd.in/eGDdTXwN
A huge thank you to everyone involved for making "AI Applications in Preclinical Assessment of ATMPs" such a success last week.
We’ll be sharing a full event write-up from this session, covering:
- Key takeaways on AI’s role
- Regulatory perspectives
- Data sharing opportunities
We’ll be sharing a full event write-up from this session, covering:
- Key takeaways on AI’s role
- Regulatory perspectives
- Data sharing opportunities
October 9, 2025 at 10:37 AM
A huge thank you to everyone involved for making "AI Applications in Preclinical Assessment of ATMPs" such a success last week.
We’ll be sharing a full event write-up from this session, covering:
- Key takeaways on AI’s role
- Regulatory perspectives
- Data sharing opportunities
We’ll be sharing a full event write-up from this session, covering:
- Key takeaways on AI’s role
- Regulatory perspectives
- Data sharing opportunities
Autolomous Ltd and the Cell and Gene Therapy Catapult have demonstrated how digital platforms can transform #cell & #gene therapy manufacturing.
Read the whitepaper to learn how digital technologies can drive scalability, efficiency & cost-effectiveness in #ATMP manufacturing: ow.ly/KGIt50X6U31
Read the whitepaper to learn how digital technologies can drive scalability, efficiency & cost-effectiveness in #ATMP manufacturing: ow.ly/KGIt50X6U31
October 6, 2025 at 8:30 AM
Autolomous Ltd and the Cell and Gene Therapy Catapult have demonstrated how digital platforms can transform #cell & #gene therapy manufacturing.
Read the whitepaper to learn how digital technologies can drive scalability, efficiency & cost-effectiveness in #ATMP manufacturing: ow.ly/KGIt50X6U31
Read the whitepaper to learn how digital technologies can drive scalability, efficiency & cost-effectiveness in #ATMP manufacturing: ow.ly/KGIt50X6U31
Regulatory update 🔔: FDA proposes guidance on using overall survival endpoints in cancer drug trials.
Learn more in the August edition of our Regulatory Round-up: ow.ly/ZaXB50WV8TT
#ATMPs #AdvancedTherapies
Learn more in the August edition of our Regulatory Round-up: ow.ly/ZaXB50WV8TT
#ATMPs #AdvancedTherapies
September 15, 2025 at 12:38 PM
Regulatory update 🔔: FDA proposes guidance on using overall survival endpoints in cancer drug trials.
Learn more in the August edition of our Regulatory Round-up: ow.ly/ZaXB50WV8TT
#ATMPs #AdvancedTherapies
Learn more in the August edition of our Regulatory Round-up: ow.ly/ZaXB50WV8TT
#ATMPs #AdvancedTherapies
Regulatory update 🔔: MHRA designated as WHO-Listed Authority - a milestone for UK life sciences and global health.
This recognition affirms the MHRA’s commitment to the highest international standards in the regulation of medical products.
Learn more: ow.ly/9mCG50WP80o
This recognition affirms the MHRA’s commitment to the highest international standards in the regulation of medical products.
Learn more: ow.ly/9mCG50WP80o
September 5, 2025 at 8:08 AM
Regulatory update 🔔: MHRA designated as WHO-Listed Authority - a milestone for UK life sciences and global health.
This recognition affirms the MHRA’s commitment to the highest international standards in the regulation of medical products.
Learn more: ow.ly/9mCG50WP80o
This recognition affirms the MHRA’s commitment to the highest international standards in the regulation of medical products.
Learn more: ow.ly/9mCG50WP80o
We're having a great time in Barcelona for Advanced Therapies Europe!
This morning Rhys Macown, one of our lead scientists, led a fantastic panel discussion as part of our Manufacturing Transformation Workshop: Automation for Optimum Patient Outcomes.
Upcoming events: ct.catapult.org.uk/events
This morning Rhys Macown, one of our lead scientists, led a fantastic panel discussion as part of our Manufacturing Transformation Workshop: Automation for Optimum Patient Outcomes.
Upcoming events: ct.catapult.org.uk/events
September 3, 2025 at 2:47 PM
We're having a great time in Barcelona for Advanced Therapies Europe!
This morning Rhys Macown, one of our lead scientists, led a fantastic panel discussion as part of our Manufacturing Transformation Workshop: Automation for Optimum Patient Outcomes.
Upcoming events: ct.catapult.org.uk/events
This morning Rhys Macown, one of our lead scientists, led a fantastic panel discussion as part of our Manufacturing Transformation Workshop: Automation for Optimum Patient Outcomes.
Upcoming events: ct.catapult.org.uk/events
The Innovate UK Biomedical Catalyst Accelerator Future Medicines is now open for applications!
We’re proud to be a partner on this national programme supporting UK innovators developing the next generation of medical treatments and technologies.
Apply today: lyvalabs.com/future-medic...
We’re proud to be a partner on this national programme supporting UK innovators developing the next generation of medical treatments and technologies.
Apply today: lyvalabs.com/future-medic...
September 1, 2025 at 11:24 AM
The Innovate UK Biomedical Catalyst Accelerator Future Medicines is now open for applications!
We’re proud to be a partner on this national programme supporting UK innovators developing the next generation of medical treatments and technologies.
Apply today: lyvalabs.com/future-medic...
We’re proud to be a partner on this national programme supporting UK innovators developing the next generation of medical treatments and technologies.
Apply today: lyvalabs.com/future-medic...
Are you following the Centre of Excellence in Regulatory Science and Innovation for Advanced Therapies (CERSI-AT) yet?
CERSI-AT drives collaborative activities to ensure the UK has a world-leading regulatory environment that best supports ATMP innovation.
Follow: www.linkedin.com/showcase/cen...
CERSI-AT drives collaborative activities to ensure the UK has a world-leading regulatory environment that best supports ATMP innovation.
Follow: www.linkedin.com/showcase/cen...
August 29, 2025 at 8:24 AM
Are you following the Centre of Excellence in Regulatory Science and Innovation for Advanced Therapies (CERSI-AT) yet?
CERSI-AT drives collaborative activities to ensure the UK has a world-leading regulatory environment that best supports ATMP innovation.
Follow: www.linkedin.com/showcase/cen...
CERSI-AT drives collaborative activities to ensure the UK has a world-leading regulatory environment that best supports ATMP innovation.
Follow: www.linkedin.com/showcase/cen...
In this interview, Mateusz Filipiak, Scientist at CGT Catapult, discusses his involvement in the SMARTER project, involving the development of a smart bioprocessing platform for autologous #CellTherapy.
Read the interview: ct.catapult.org.uk/news/r-d-pro...
Read the interview: ct.catapult.org.uk/news/r-d-pro...
August 27, 2025 at 3:52 PM
In this interview, Mateusz Filipiak, Scientist at CGT Catapult, discusses his involvement in the SMARTER project, involving the development of a smart bioprocessing platform for autologous #CellTherapy.
Read the interview: ct.catapult.org.uk/news/r-d-pro...
Read the interview: ct.catapult.org.uk/news/r-d-pro...
Scottish academics – applications close in less than 1 week! 🚨
Apply to our competition to gain expert support in developing a Target Product Profile (TPP) for your #AdvancedTherapy
Check out how we supported two academics from the University of Aberdeen below 👇
Apply now: lnkd.in/etGYMQzq
Apply to our competition to gain expert support in developing a Target Product Profile (TPP) for your #AdvancedTherapy
Check out how we supported two academics from the University of Aberdeen below 👇
Apply now: lnkd.in/etGYMQzq
August 20, 2025 at 8:11 AM
Scottish academics – applications close in less than 1 week! 🚨
Apply to our competition to gain expert support in developing a Target Product Profile (TPP) for your #AdvancedTherapy
Check out how we supported two academics from the University of Aberdeen below 👇
Apply now: lnkd.in/etGYMQzq
Apply to our competition to gain expert support in developing a Target Product Profile (TPP) for your #AdvancedTherapy
Check out how we supported two academics from the University of Aberdeen below 👇
Apply now: lnkd.in/etGYMQzq
Regulatory update 🔔: MHRA's new modular manufacture and point of care regulations have come into effect.
Hospitals in the UK now have a pathway to carry out the manufacturing steps for treatments near or on-site.
Learn more in the July edition of our Regulatory Round-up: lnkd.in/eJzKsy-e
Hospitals in the UK now have a pathway to carry out the manufacturing steps for treatments near or on-site.
Learn more in the July edition of our Regulatory Round-up: lnkd.in/eJzKsy-e
August 12, 2025 at 8:26 AM
Regulatory update 🔔: MHRA's new modular manufacture and point of care regulations have come into effect.
Hospitals in the UK now have a pathway to carry out the manufacturing steps for treatments near or on-site.
Learn more in the July edition of our Regulatory Round-up: lnkd.in/eJzKsy-e
Hospitals in the UK now have a pathway to carry out the manufacturing steps for treatments near or on-site.
Learn more in the July edition of our Regulatory Round-up: lnkd.in/eJzKsy-e
Regulatory update 🔔: MHRA CEO Lawrence Tallon welcomes UK government's Life Sciences Sector Plan
The document, in which the CGT Catapult plays a key part, sets out a vision and action plan to drive growth, innovation, and better health outcomes across the UK.
Learn more: lnkd.in/eJzKsy-e
#ATMPs
The document, in which the CGT Catapult plays a key part, sets out a vision and action plan to drive growth, innovation, and better health outcomes across the UK.
Learn more: lnkd.in/eJzKsy-e
#ATMPs
August 8, 2025 at 1:16 PM
Regulatory update 🔔: MHRA CEO Lawrence Tallon welcomes UK government's Life Sciences Sector Plan
The document, in which the CGT Catapult plays a key part, sets out a vision and action plan to drive growth, innovation, and better health outcomes across the UK.
Learn more: lnkd.in/eJzKsy-e
#ATMPs
The document, in which the CGT Catapult plays a key part, sets out a vision and action plan to drive growth, innovation, and better health outcomes across the UK.
Learn more: lnkd.in/eJzKsy-e
#ATMPs
The Centre of Excellence in Regulatory Science & Innovation for Advanced Therapies (CERSI-AT) is on LinkedIn!
Coordinated by us & Birmingham Health Partners CRSI, CERSI-AT ensures the UK has a world-leading regulatory environment for ATMP innovation.
Follow today: www.linkedin.com/showcase/108...
Coordinated by us & Birmingham Health Partners CRSI, CERSI-AT ensures the UK has a world-leading regulatory environment for ATMP innovation.
Follow today: www.linkedin.com/showcase/108...
August 6, 2025 at 8:20 AM
The Centre of Excellence in Regulatory Science & Innovation for Advanced Therapies (CERSI-AT) is on LinkedIn!
Coordinated by us & Birmingham Health Partners CRSI, CERSI-AT ensures the UK has a world-leading regulatory environment for ATMP innovation.
Follow today: www.linkedin.com/showcase/108...
Coordinated by us & Birmingham Health Partners CRSI, CERSI-AT ensures the UK has a world-leading regulatory environment for ATMP innovation.
Follow today: www.linkedin.com/showcase/108...
We're gathering insights from stakeholders across the ecosystem to better understand the current landscape and challenges of applying AI in the development and assessment of #ATMPs.
Share your insights with us in this short survey: lnkd.in/eBkPyYa8
#AdvancedTherapies #AI #CellTherapy #GeneTherapy
Share your insights with us in this short survey: lnkd.in/eBkPyYa8
#AdvancedTherapies #AI #CellTherapy #GeneTherapy
August 5, 2025 at 9:02 AM
We're gathering insights from stakeholders across the ecosystem to better understand the current landscape and challenges of applying AI in the development and assessment of #ATMPs.
Share your insights with us in this short survey: lnkd.in/eBkPyYa8
#AdvancedTherapies #AI #CellTherapy #GeneTherapy
Share your insights with us in this short survey: lnkd.in/eBkPyYa8
#AdvancedTherapies #AI #CellTherapy #GeneTherapy
Applications are now open to our competition for Scottish academics looking for support to develop a target product profile (TPP) and quality target product profile (QTPP) for their #AdvancedTherapy or vaccine 🚨
Application deadline: 26th August 2025
Apply today: ct.catapult.org.uk/p/tpp
Application deadline: 26th August 2025
Apply today: ct.catapult.org.uk/p/tpp
July 30, 2025 at 8:38 AM
Applications are now open to our competition for Scottish academics looking for support to develop a target product profile (TPP) and quality target product profile (QTPP) for their #AdvancedTherapy or vaccine 🚨
Application deadline: 26th August 2025
Apply today: ct.catapult.org.uk/p/tpp
Application deadline: 26th August 2025
Apply today: ct.catapult.org.uk/p/tpp
In the first investment from the CGT Catapult as part of the Cross-Catapult Investment Pilot, Spliceor has received funding to accelerate the pre-clinical development of its trans-splicing #GeneTherapy platform for liver cancer.
Learn more: lnkd.in/e4h9xNkQ
@catapultnetwork.bsky.social
Learn more: lnkd.in/e4h9xNkQ
@catapultnetwork.bsky.social
July 22, 2025 at 10:52 AM
In the first investment from the CGT Catapult as part of the Cross-Catapult Investment Pilot, Spliceor has received funding to accelerate the pre-clinical development of its trans-splicing #GeneTherapy platform for liver cancer.
Learn more: lnkd.in/e4h9xNkQ
@catapultnetwork.bsky.social
Learn more: lnkd.in/e4h9xNkQ
@catapultnetwork.bsky.social
See our response to the recent publication of the Government's Life Sciences Sector Plan, learn more about the plan and how advanced therapies can play a key part:
ct.catapult.org.uk/news/cgt-cat...
#LifeSciencesSectorPlan #ATMPs #LifeSciences
ct.catapult.org.uk/news/cgt-cat...
#LifeSciencesSectorPlan #ATMPs #LifeSciences
July 16, 2025 at 12:19 PM
See our response to the recent publication of the Government's Life Sciences Sector Plan, learn more about the plan and how advanced therapies can play a key part:
ct.catapult.org.uk/news/cgt-cat...
#LifeSciencesSectorPlan #ATMPs #LifeSciences
ct.catapult.org.uk/news/cgt-cat...
#LifeSciencesSectorPlan #ATMPs #LifeSciences
Regulatory update 🔔: MHRA leads safe use of AI in healthcare as first country in new global network.
The move puts the MHRA at the centre of global efforts to get trusted AI tools safely into clinics faster
Learn more in the June edition of our Regulatory Round-up: ow.ly/ABbp50Woakh
The move puts the MHRA at the centre of global efforts to get trusted AI tools safely into clinics faster
Learn more in the June edition of our Regulatory Round-up: ow.ly/ABbp50Woakh
July 16, 2025 at 8:44 AM
Regulatory update 🔔: MHRA leads safe use of AI in healthcare as first country in new global network.
The move puts the MHRA at the centre of global efforts to get trusted AI tools safely into clinics faster
Learn more in the June edition of our Regulatory Round-up: ow.ly/ABbp50Woakh
The move puts the MHRA at the centre of global efforts to get trusted AI tools safely into clinics faster
Learn more in the June edition of our Regulatory Round-up: ow.ly/ABbp50Woakh
Subscribe to the Cell and Gene Therapy Catapult newsletter today 📩
Click this link to get the latest news, industry reports and event announcements sent straight to your inbox: lnkd.in/e4xpEHKX
#CellTherapy #GeneTherapy #ATMPs #AdvancedTherapies
Click this link to get the latest news, industry reports and event announcements sent straight to your inbox: lnkd.in/e4xpEHKX
#CellTherapy #GeneTherapy #ATMPs #AdvancedTherapies
July 10, 2025 at 11:34 AM
Subscribe to the Cell and Gene Therapy Catapult newsletter today 📩
Click this link to get the latest news, industry reports and event announcements sent straight to your inbox: lnkd.in/e4xpEHKX
#CellTherapy #GeneTherapy #ATMPs #AdvancedTherapies
Click this link to get the latest news, industry reports and event announcements sent straight to your inbox: lnkd.in/e4xpEHKX
#CellTherapy #GeneTherapy #ATMPs #AdvancedTherapies
Regulatory update 🔔: New Post-Market Surveillance regulation took effect across Great Britain in June 2025, requiring medical device manufacturers to proactively monitor the safety and performance of their products once on the market.
Learn more in our June Regulatory Round-up: ow.ly/KyGe50WkU3z
Learn more in our June Regulatory Round-up: ow.ly/KyGe50WkU3z
July 8, 2025 at 12:54 PM
Regulatory update 🔔: New Post-Market Surveillance regulation took effect across Great Britain in June 2025, requiring medical device manufacturers to proactively monitor the safety and performance of their products once on the market.
Learn more in our June Regulatory Round-up: ow.ly/KyGe50WkU3z
Learn more in our June Regulatory Round-up: ow.ly/KyGe50WkU3z
CAR T Vision, an international coalition uniting healthcare stakeholders to improve patient access to CAR T-cell therapy, has launched their CAR T Vision and Roadmap Report.
The report outlines recommendations to help the industry increase patient access to CAR T therapy: ow.ly/VZia50WaC8h
The report outlines recommendations to help the industry increase patient access to CAR T therapy: ow.ly/VZia50WaC8h
June 17, 2025 at 11:00 AM
CAR T Vision, an international coalition uniting healthcare stakeholders to improve patient access to CAR T-cell therapy, has launched their CAR T Vision and Roadmap Report.
The report outlines recommendations to help the industry increase patient access to CAR T therapy: ow.ly/VZia50WaC8h
The report outlines recommendations to help the industry increase patient access to CAR T therapy: ow.ly/VZia50WaC8h
Regulatory update 🔔: European Pharmacopoeia Commission (EPC) adopts mycoplasma general chapter and monographs, updated to incorporate latest analytical developments.
Learn more about the specifics of the revised general chapter in the May edition of our Regulatory Round-up: ow.ly/xCB650W8SGY
Learn more about the specifics of the revised general chapter in the May edition of our Regulatory Round-up: ow.ly/xCB650W8SGY
June 17, 2025 at 8:13 AM
Regulatory update 🔔: European Pharmacopoeia Commission (EPC) adopts mycoplasma general chapter and monographs, updated to incorporate latest analytical developments.
Learn more about the specifics of the revised general chapter in the May edition of our Regulatory Round-up: ow.ly/xCB650W8SGY
Learn more about the specifics of the revised general chapter in the May edition of our Regulatory Round-up: ow.ly/xCB650W8SGY
@nicolemather.bsky.social delivered a powerful talk on how AI & digital technologies can transform ATMP production at our CGT Catapult & Alliance for Regenerative Medicine Industrialisation workshop today!
Key areas included: data standardisation, platform scale out & flexible automation.
Key areas included: data standardisation, platform scale out & flexible automation.
June 12, 2025 at 3:25 PM
@nicolemather.bsky.social delivered a powerful talk on how AI & digital technologies can transform ATMP production at our CGT Catapult & Alliance for Regenerative Medicine Industrialisation workshop today!
Key areas included: data standardisation, platform scale out & flexible automation.
Key areas included: data standardisation, platform scale out & flexible automation.
Yesterday, Lord Vallance, Minister of State for Science, Research and Innovation, opened our Digital and Automation Testbeds that have been developed to improve #AdvancedTherapy manufacturing.
Learn more: ct.catapult.org.uk/news/science...
#ATMPs #CellTherapy #GeneTherapy #AdvancedTherapies
Learn more: ct.catapult.org.uk/news/science...
#ATMPs #CellTherapy #GeneTherapy #AdvancedTherapies
June 12, 2025 at 9:38 AM
Yesterday, Lord Vallance, Minister of State for Science, Research and Innovation, opened our Digital and Automation Testbeds that have been developed to improve #AdvancedTherapy manufacturing.
Learn more: ct.catapult.org.uk/news/science...
#ATMPs #CellTherapy #GeneTherapy #AdvancedTherapies
Learn more: ct.catapult.org.uk/news/science...
#ATMPs #CellTherapy #GeneTherapy #AdvancedTherapies
Regulatory update 🔔
The @fda.gov has approved Zevaskyn an autologous cell sheet-based gene therapy, indicated for treatment of wounds in adult & paediatric patients with recessive dystrophic epidermolysis bullosa.
Learn more in the May edition of our monthly Regulatory Round-up: ow.ly/PXsA50W5m3H
The @fda.gov has approved Zevaskyn an autologous cell sheet-based gene therapy, indicated for treatment of wounds in adult & paediatric patients with recessive dystrophic epidermolysis bullosa.
Learn more in the May edition of our monthly Regulatory Round-up: ow.ly/PXsA50W5m3H
June 10, 2025 at 8:25 AM
Regulatory update 🔔
The @fda.gov has approved Zevaskyn an autologous cell sheet-based gene therapy, indicated for treatment of wounds in adult & paediatric patients with recessive dystrophic epidermolysis bullosa.
Learn more in the May edition of our monthly Regulatory Round-up: ow.ly/PXsA50W5m3H
The @fda.gov has approved Zevaskyn an autologous cell sheet-based gene therapy, indicated for treatment of wounds in adult & paediatric patients with recessive dystrophic epidermolysis bullosa.
Learn more in the May edition of our monthly Regulatory Round-up: ow.ly/PXsA50W5m3H